A novel serum-based assay of functional IgG inhibitory activity is predictive of the clinical response to immunotherapy

一种新的基于血清的功能性 IgG 抑制活性测定可预测免疫治疗的临床反应

• 批准号: G0601303/1
• 负责人: Stephen Durham
• 金额: $ 22.93万
• 依托单位: Imperial College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2007
• 资助国家: 英国
• 起止时间: 2007 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0601303%2F1
• 关键词: novel; serum; based; assay; functional

Hayfever affects 12 million people in UK and may ruin what for most of us is the best time of the year. Hayfever impairs concentration at work and may reduce performance in school exams. Many sufferers respond to antihistamines and nasal steroid sprays. There remains a hard core who may benefit from allergy vaccination (desensitisation injections). Discovered in UK 100 years ago, this treatment is highly effective but requires specialist supervision . We have developed in partnership with a company, ALK Abello, an alternative, effective and safer vaccine containing grass extract that is taken daily as a rapidly dissolving tablet under the tongue (GRAZAX). Based on our understanding of how vaccination works, we now wish to develop a test that measures ‘protective’ antibodies in the bloodstream that will allow us to predict those patients who are likely to respond best to desensitisation and to monitor the effects of treatment.

花粉热影响着英国 1200 万人，并可能毁掉我们大多数人一年中最好的时光。花粉症会影响工作注意力，并可能降低学校考试的成绩。许多患者对抗组胺药和鼻类固醇喷雾剂有反应。仍然有一些核心人员可能会受益于过敏疫苗接种（脱敏注射）。这种疗法于 100 年前在英国发现，非常有效，但需要专家监督。我们与 ALK Abello 公司合作开发了一种替代、有效且更安全的疫苗，含有草提取物，每天以舌下快速溶解片剂形式服用 (GRAZAX)。基于我们对疫苗接种原理的理解，我们现在希望开发一种测试来测量血液中的“保护性”抗体，这将使我们能够预测那些可能对脱敏反应最佳的患者并监测治疗效果。